The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study

Table 3 Relationships between ECG abnormalities and chemotherapeutic drugs

Drug	Total (cases)	ST-T segment abnormalities			Elevated myocardial enzymes			Arrhythmia			QRS pattern or duration abnormalities
Drug	Total (cases)	No. of events [cases (%)]	χ²	P value	No. of events [cases (%)]	χ²	P value	No. of events [cases (%)]	χ²	P value	No. of events [cases (%)]	χ²	P value
Anthracyclines	89	32 (36.0)	3.031	0.082	3 (3.4)	0.007	0.935	30 (33.7)	0.274	0.601	12 (13.5)	4.104	0.043
Cyclophosphamide	81	27 (33.3)	0.629	0.428	2 (2.5)	0.000	1.000	28 (34.6)	0.051	0.821	10 (12.3)	1.667	0.197
Paclitaxel	62	18 (29.0)	0.126	0.723	2 (3.2)	0.000	1.000	20 (32.3)	0.455	0.500	6 (9.7)	0.003	0.957
Docetaxel	59	13 (22.0)	3.414	0.065	2 (3.4)	0.000	1.000	25 (42.4)	2.112	0.146	4 (6.8)	0.411	0.521
Carboplatin	43	8 (18.6)	4.126	0.042	2 (2.3)	0.135	0.713	16 (37.2)	0.090	0.765	2 (4.6)	0.971	0.324

ISSN: 2523-3548